Table 7.
Laboratory Abnormalities in Patients with Normal Values at Baseline for the Pooled Studies Safety Population
| Proportion (%) of patients | ||
| Variable | Telavancin group | Vancomycin group |
| Hematocrit | ||
| Male sex, ≤30% | 13/99 (13) | 17/106 (16) |
| Female sex, ≤28% | 15/97 (15) | 16/93 (17) |
| WBC count <2800 cells/μL | 1/251 (<1) | 6/243 (2) |
| Platelet count ≤75,000 platelets/μL | 6/370 (2) | 10/403 (2) |
| AST level ≥3 ULN | 23/359 (6) | 17/358 (5) |
| ALT level ≥3 ULN | 22/398 (6) | 33/411 (8) |
| Alkaline phosphatase level ≥2 ULN | 23/469 (5) | 40/505 (8) |
| Potassium level <3 meq/L | 50/587 (9) | 37/579 (6) |
| Potassium level >5.5 meq/L | 33/587 (6) | 32/579 (6) |
| Creatinine level increase a | 111/716 (16) | 69/723 (10) |
NOTE. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; WBC, white blood cell.
a
Serum creatinine level increased >50% from baseline and with a maximum value >1.5 mg/dL regardless of the initial value; includes patients with abnormal serum creatinine levels at baseline.